NASDAQ OMX

Apricus Biosciences Provides Corporate Update and Second Quarter 2017 Financial Results

Del

Vitaros Drug-Device Human Factor Studies Successfully Completed

Vitaros U.S. NDA Final Draft Completed with Re-Submission Expected in Current Quarter

Conference Call / Webcast Today, August 2, 2017 at 4:30 p.m. ET

SAN DIEGO, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today reported financial results for the second quarter of 2017 and provided a corporate update on its priorities for the remainder of the year.

"In the second quarter of this year, we continued to execute on our strategy by creating a stable, financially healthier organization focused on resubmission of the Vitaros NDA," stated Richard W. Pascoe, Chief Executive Officer. "We have improved our financial outlook through a combination of fundraising and expense reduction, resulting in a balance sheet that is expected to fund our current operating plan through the third quarter of 2018.  Importantly, we have completed the final draft of the Vitaros NDA and we expect to re-submit the Vitaros NDA this quarter with an anticipated FDA approval decision in the first quarter of 2018.  For the remainder of 2017, we will focus on working with the FDA regarding the Vitaros NDA, maintaining a productive dialogue with Allergan regarding the commercial potential for Vitaros in the United States, securing a development partner for RayVa, and continuing to diligently manage our corporate resources."

Recent Highlights

Apricus continues to execute on its corporate strategy as highlighted below:

Vitaros(TM) (alprostadil)

  • Continued implementation of the U.S. regulatory approval strategy to address issues raised by the FDA in the original Vitaros NDA submission.  Specifically, all safety, chemistry, manufacturing and control (CMC) related issues raised in the original Non-Approvable Letter will be addressed in the re-submission.  In addition, Apricus has confirmed the necessary drug-device engineering and compliance requirements, including human factor testing, and those studies are now complete; and
  • Continued to ensure a smooth transition of the Vitaros ex-US rights and assets to Ferring International.  Under the agreement, Apricus has received approximately $12.45 million to date, including an upfront payment of $11.5 million, approximately $0.7 million for the delivery of certain product-related inventory and $0.25 million related to transition services.  Apricus is eligible to receive an additional $0.25 million payment related to transition services, subject to certain limitations, during the third quarter of 2017.

RayVa(TM) (alprostadil)

  • Continued a partnering process to secure a global or regional RayVa partnership prior to initiating a Phase 2b clinical study.

Corporate/Financial

  • Closed on an underwritten public offering of common stock and warrants for gross proceeds of approximately $7.0 million; and
  • Regained compliance with all criteria for continued listing on The NASDAQ Capital Market.

Second Quarter and Year-to-Date Financial Results

Net loss for the quarter ended June 30, 2017 was $1.5 million, or loss per share of $0.13, compared to a net loss of $3.3 million, or loss per share of $0.54, for the second quarter of 2016. Net loss during the second quarter of 2017 was primarily due to expenses related to the preparation of our resubmission of the Vitaros NDA and other general and administrative expenses.

Net income for the six months ended June 30, 2017 was $6.6 million, or income per share of $0.69, compared to a net loss of $5.8 million, or loss per share of $1.00, for the second quarter of 2016. Net income during the six months ended June 30, 2017 was primarily due to the $12.1 million gain recorded for the sale of our ex-U.S. Vitaros rights and assets to Ferring.

For all periods presented, financial statement activity related to our ex-U.S. Vitaros business has been presented as discontinued operations.  As of June 30, 2017, the Company's cash totaled $7.8 million, compared to $2.1 million as of December 31, 2016.

Conference Call Details

Apricus will host a live conference call and webcast today at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide a corporate update. To participate by telephone, please dial (855) 780-7196 (Domestic) or (631) 485-4867 (International).  The conference ID number is 58725002. The live and archived audio webcast can be accessed through the Investors Relations' section of the Company's website at www.apricusbio.com. Please log in approximately five to ten minutes before the event to ensure a timely connection. The archived webcast will be available for 30 days following the live call.

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus has two product candidates currently in development. Vitaros is a product candidate in the United States for the treatment of erectile dysfunction, which is in-licensed from Warner Chilcott Company, Inc., now a subsidiary of Allergan plc (Allergan). RayVa is our product candidate in Phase 2 development for the treatment of the circulatory disorder Raynaud's phenomenon, secondary to scleroderma, for which we own worldwide rights.

For further information on Apricus, visit http://www.apricusbio.com.

Vitaros(TM) is Apricus' trademark in the United States, which is pending registration and subject to the agreement with Allergan.  Vitaros® is a registered trademark of Ferring International Center S.A. in certain countries outside of the United States.  RayVa(TM) is Apricus' trademark, which is registered in certain countries throughout the world and pending registration in the United States.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act, as amended. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things: Apricus' ability to transition its ex-U.S. assets and rights related to Vitaros to Ferring and receive the second transition services payment from Ferring; the timing of regulatory submission and approval of Vitaros in the United States, if any; Apricus' development and partnering plans for RayVa; Apricus' plans to reduce operating expenses, including projected 2017 cost savings; and Apricus' strategic objectives. Actual results could differ from those projected in any forward-looking statements due to a variety of reasons that are outside the control of Apricus, including, but not limited to: the risk that Apricus fails to provide the transition services as required by the transition services agreement with Ferring; the risk that the cost and other negative effects related to the reduction of Apricus' workforce may be greater than anticipated; the risk that Apricus may not realize the benefits expected from cost control measures; competition in the erectile dysfunction market and other markets in which Apricus operates; Apricus' ability to obtain FDA and other requisite governmental approval for Vitaros; Apricus' ability to further develop Vitaros, such as delivery device improvements; Apricus' ability to carry out further clinical studies for Vitaros, if required, as well as the timing and success of the results of such studies; the failure to remain in compliance with NASDAQ continued listing requirements which could result in Apricus' common stock being delisted from the exchange; Apricus' ability to retain and attract key personnel; Apricus' ability to raise additional funding that it may need to continue to pursue its commercial and business development plans; Apricus' ability to secure a  strategic partner for RayVa; and market conditions. These forward-looking statements are made as of the date of this press release, and Apricus assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Readers are urged to read the risk factors set forth in Apricus' most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q, and other filings made with the SEC. Copies of these reports are available from the SEC's website at www.sec.gov or without charge from Apricus.

(Financial Information to Follow)


Selected Financial Information
Condensed Consolidated Statements of Operations
(In thousands, except per share amounts)
 
  Three Months Ended
 June 30,
  Six Months Ended
 June 30,
  2017   2016   2017   2016
Operating expense              
Research and development $ (839 )   $ (2,503 )   $ (1,266 )   $ (5,104 )
General and administrative (1,602 )   (2,122 )   (3,043 )   (4,328 )
Total other income (expense) 719     1,372     (832 )   3,684  
Loss from continuing operations (1,722 )   (3,253 )   (5,141 )   (5,748 )
Income (loss) from discontinued operations 248     (85 )   11,740     (95 )
Net income (loss) $ (1,474 )   $ (3,338 )   $ 6,599     $ (5,843 )
               
Basic and diluted earnings (loss) per share              
Continuing operations $ (0.15 )   $ (0.53 )   $ (0.54 )   $ (0.98 )
Discontinued operations $ 0.02     $ (0.01 )   $ 1.23     $ (0.02 )
Total earnings (loss) per share $ (0.13 )   $ (0.54 )   $ 0.69     $ (1.00 )
               
Weighted average common shares outstanding for basic and diluted earnings (loss) per share 11,335     6,182     9,547     5,843  

Condensed Consolidated Balance Sheets
(In thousands)
 
  June 30,
 2017
  December 31,
 2016
  (Unaudited)    
Assets      
Cash $ 7,821     $ 2,087  
Other current assets 322     177  
Property and equipment, net 121     164  
Other long term assets 45     60  
Assets of discontinued operations $ 506     $ 2,212  
Total assets $ 8,815     $ 4,700  
       
Liabilities and stockholders' equity (deficit)      
Current liabilities $ 1,513     $ 2,536  
Current liabilities of discontinued operations 331     2,108  
Notes payable, net -     6,650  
Warrant liabilities 339     846  
Other long term liabilities 60     76  
Stockholders' equity (deficit) 6,572     (7,516 )
Total liabilities and stockholders' equity (deficit) $ 8,815     $ 4,700  

CONTACT:

Matthew Beck
mbeck@troutgroup.com
The Trout Group
(646) 378-2933




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Apricus Biosciences, Inc. via Globenewswire

Om NASDAQ OMX

NASDAQ OMX
NASDAQ OMX
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra NASDAQ OMX

Registrer deg med din epostadresse under for å få de nyeste sakene fra NASDAQ OMX på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra NASDAQ OMX

NTT Security Launches Security Services for Industrial Control Systems20.9.2017 10:00Pressemelding

Cyber-defense for critical infrastructure including factories, plants, utilities & hospitals TOKYO, Sept. 20, 2017 (GLOBE NEWSWIRE) -- NTT Security Corporation (Head Office: Chiyoda-Ku, Tokyo; CEO: Jun Sawada), the specialized security company of NTT Group, has launched "IT/OT Integrated Security Services". The new services will be taken to market globally through the NTT Group companies, Dimension Data, NTT Communications and NTT DATA, forming part of its suite of integrated services to enable successful digital transformation initiatives for its clients. Companies are increasingly working towards IT/OT (Operational Technology) alignment. OT systems, when connected to the internet, streamline business operations by advanced supply chain management, realization of mass customization and improvement of customer experience as well as find new intelligence employing IoT (the Internet of Things) and Big Data analytics. As a result, IT/OT convergence is ex

NTT Security lanserer sikkerhetstjenester for industrielle kontrollsystemer20.9.2017 10:00Pressemelding

Cyberforsvar for kritisk infrastruktur, inkludert fabrikker, anlegg, forsyningstjenester og sykehus Oslo, 20. sept. 2017 (GLOBE NEWSWIRE) - NTT Security Corporation (hovedkontor: Chiyoda-Ku, Tokyo; adm.dir.: Jun Sawada), det spesialiserte sikkerhetsselskapet til NTT Group, har lansert IT/OT Integrated Security Services. De nye tjenestene skal markedsføres globalt gjennom NTT Group-selskapene Dimension Data, NTT Communications og NTT DATA. De inngår i en pakke med integrerte tjenester som gjør det mulig for kundene å gjennomføre digitale transformasjonsinitiativ. Selskaper arbeider i økende grad med tilpasning av IT/OT (operativ teknologi). Når OT-systemer kobles til internett, kan de effektivisere forretningsvirksomheten gjennom avansert styring av forsyningskjeden, realisering av massetilpasning og forbedring av kundeopplevelsen, samt utvikle ny intelligens som benytter IoT (Internet of Things, tingenes internett) og stordataanalyse. Som et resultat av dette gjør IT/OT-k

Zumio(TM) Now Available in Europe20.9.2017 08:00Pressemelding

Exclusive Partnership Agreement Signed with Eropartner Distribution Ottawa, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Zumio Inc. proudly announces it has partnered exclusively with Eropartner Distribution for distribution across all 28 EU member countries. Winner of the  Best New Product at ADULTEX 2017, Zumio is the world's only clitoral stimulator based on the proven circular fingertip motion. Zumio's patented SpiroTIP(TM) and motor clutch drive system allows users to dynamically go from high speed and intensity down to a low speed and intensity, without having to touch a control, to instinctively and more naturally, adjust the stimulation to suit their needs. "Traditional vibrators generate excess energy and shake everything they touch often creating sensory overload and a numbing effect," said Steve Traplin, Chief Revenue Officer at Zumio. " Our non-vibrating technology makes Zumio more comfortable to hold and the small TIP and

Juniper Systems Limited Eyes German Market with InterGeo 2017 Exhibit, Opens New Office in Wels, Austria20.9.2017 04:16Pressemelding

BIRMINGHAM, United Kingdom, Sept.  19, 2017  (GLOBE NEWSWIRE) -- Manufacturer of rugged handheld data collectors Juniper Systems Limited aims to expand its footprint in the German marketplace. Coinciding with the opening of its new office in Wels, Austria, the company will exhibit at the geometrics industry trade fair, InterGeo 2017, next week in Berlin, Germany. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/ec8e4e2c-b277-48f9-bce9-4606d17454a5 The Wels location was recently opened to serve German-speaking partners and customers in Austria, Germany, and other Eastern European countries. Juniper Systems will showcase its ultra-rugged solutions for GIS, geomatics and geoinformation applications in Hall 1.1 on Stand C1.010 on 26 - 28 September at InterGeo. 'We're excited to be exhibiting at the InterGeo trade fair, which is now a regular date in our diary', commented Simon Bowe, general manager of Juni

CallidusCloud Unveils Game-Changing Augmented Intelligence Platform for Sales Performance, Execution and Learning Customers19.9.2017 22:35Pressemelding

Thunderbridge AI³ Combines the Power of Artificial Intelligence, Application Integration, and Human Insight to Provide Contextual Augmented Intelligence Recommendations throughout the Lead to Money suite DUBLIN, Calif., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Callidus Software Inc. (NASDAQ:CALD), a global leader in cloud-based sales, marketing, learning, and customer experience solutions, unveiled its newest platform, Thunderbridge Augmented Intelligence - or Thunderbridge AI³ - today at CallidusCloud Connections (C3) 2017, its annual user conference. The new solution is comprised of three elements: artificial intelligence, application integration, and human insight. The Thunderbridge Augmented Intelligence platform is a layer of software that applies machine learning techniques to the sales and learning processes to come up with recommended actions for increasing revenue, profit, and sales effectiveness. The role of human insight and behavior is key to Thunderbridge AI

Merus Announces Second Quarter 2017 Financial Results and Highlights Recent Progress19.9.2017 22:05Pressemelding

Merus Announces Second Quarter 2017 Financial Results and Highlights Recent Progress UTRECHT, The Netherlands, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced financial results for the second quarter ended June 30, 2017 and provided a corporate and clinical update. "Merus has had a productive year to date, marked by progress in our work with Incyte and our other collaborators, the presentation at ASCO of positive Phase 1/2 data for our lead candidate MCLA-128 in the first of several indications, and progress among a stable of very exciting Biclonics®-based bispecific antibody therapy candidates toward and through the clinic," said Ton Logtenberg, Ph.D., Chief Executive Officer of Merus.  "We believe that the potential of Merus' Biclonics® platform, which holds a number of key advantages over other bispecific antibody a

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom